FDA mulls extending Arexvy approval to people ages 50 to 59

The FDA expects to make a decision by early June.

Related Keywords

Zhongsheng , Anhui , China , Chinese , Lynda Coughlan , Bowonpat Sakaew , Kathleen Neuzil , University Of Maryland School Medicine Center , Global Health , Vaccine Development , Lancet Infectious , Zhongsheng Pharmaceutical , Maryland School , Medicine Center ,